The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

Essure is a permanent, non-surgical birth control device for women developed by Conceptus Inc., a company owned by Bayer. Essure was approved for use in the United States in 2002.The Food & Drug Administration (FDA) announced the requirement for Bayer (the manufacturer of the Essure device) to conduct clinical studies and potentially issue “black box” warnings after thousands of patients reported complaints of the Essure device. When you chose to undergo a permanent birth control procedure, you likely do so in full faith that it will result in a safe and effective means of preventing pregnancy. What you might not have known is that procedures involving permanent fallopian tube implants such as Essure® have reportedly caused a host of serious side effects and complications in thousands of women ranging from chronic pelvic pain to even death. The health complications are due to the fact that the inserts contain nickel-titanium alloys, a material known to cause allergic reactions. Once the inserts are placed in the body, they release nickel into the tubes and patients who are allergic to nickel may have serious allergic reactions. Symptoms of a reaction include rash, itching, and hives. If you are currently using Essure and are experiencing these symptoms, you may be in danger of facing detrimental side effects. In addition to allergic reactions, Essure can cause other complications, including:

Pain/Abdominal Pain

Heavier/ Irregular Menstruation

Fatigue

Weight Fluctuations

Device Breakage

Dyspareunia

Malposition of the Device

Hysterectomies;

Colon perforation due to device moving;

Pregnancy

If you or a loved one  suffered any of the aforementioned conditions from use of Essure please  contact Jamie Sheller Esq.  at Sheller PC for a FREE consultation at 1-800-883- 2299

Comments for this article are closed.